Bacterial infections that no longer respond to standard antibiotics are projected to kill approximately 39 million people between now and 2050, a toll that would represent a roughly 70 percent increase over recent levels. The forecast comes from the Global Research on Antimicrobial Resistance (GRAM) project, a systematic analysis covering 204 countries and territories published in The Lancet. In September 2024, global leaders responded by committing to cut deaths associated with bacterial antimicrobial resistance (AMR) by 10 percent by 2030, measured against a 2019 baseline, but the gap between that pledge and the scale of the projected crisis raises hard questions about whether the target goes far enough.
Why the 39 million death forecast demands immediate action
The numbers behind this projection are grounded in a well-documented baseline. A prior GRAM systematic analysis established that in 2019, approximately 4.95 million deaths were associated with bacterial AMR, and roughly 1.27 million of those deaths were directly attributable to resistant infections. Those figures made drug-resistant bacteria one of the leading causes of death worldwide that year, killing more people than HIV/AIDS or malaria individually.
The newer GRAM study extends that record through 2021 and then models several scenarios out to 2050. Under its baseline trajectory, the cumulative death toll reaches approximately 39 million, according to the peer-reviewed analysis published in The Lancet. The projected 70 percent rise is not uniform across regions or age groups. Older adults and populations in lower-resource settings face the steepest increases, driven by aging demographics, limited access to newer antibiotics, and weaker infection-prevention infrastructure.
The political response so far centers on a target adopted at the United Nations High-Level Meeting on Antimicrobial Resistance in September 2024. Global leaders committed to reducing deaths associated with bacterial AMR by 10 percent by 2030, using the 2019 figure of 4.95 million associated deaths as the benchmark. If that target is met, it would mean roughly 495,000 fewer associated deaths per year by 2030 compared to the baseline. Sustained at that rate through 2050, the cumulative reduction could exceed 4 million deaths relative to the no-action forecast. That is a meaningful number, but it would still leave tens of millions of projected deaths unaddressed, suggesting the 10 percent goal functions more as a floor than a ceiling for ambition.
How the GRAM modeling built its 2050 projections
The GRAM project, led by researchers affiliated with the Institute for Health Metrics and Evaluation (IHME), drew on an extensive dataset spanning records from 1990 through 2021 to build its historical estimates. The analysis covered multiple bacterial pathogens, drug-resistance combinations, and clinical syndromes across 204 countries and territories. From that foundation, the team generated forecasts through 2050 under several scenarios, including a baseline case and alternatives that modeled the impact of improved infection prevention, better access to antibiotics, and expanded stewardship programs.
The distinction between “associated” and “attributable” deaths is central to reading the results correctly. The 4.95 million associated deaths in 2019 include all cases where a resistant bacterium played a role, even if the patient might have died from the underlying infection regardless. The 1.27 million directly attributable deaths count only those cases where resistance itself was the difference between survival and death. Both figures come from the same GRAM framework and have been widely cited in global health discussions of AMR burden.
The 39 million projection through 2050 reflects the broader associated-death measure, which captures the full burden of resistant infections on health systems. That framing matters for policymakers: associated deaths encompass the extra days in hospital, the need for more toxic or expensive drugs, and the cascading strain on intensive care units when first-line therapies fail. Even if some of those patients might have died from their infections anyway, resistance makes their care more complex, more costly, and more likely to end badly.
The study’s scenario modeling also highlights a tension: some regions have made progress on infection control and antibiotic stewardship, yet the global death toll is still expected to climb. Population aging is a key driver. As more people worldwide live into their 70s and 80s, they become more vulnerable to infections that would once have been treatable. Resistance rates among common hospital-acquired pathogens, including certain strains of Escherichia coli and Staphylococcus aureus, continue to rise in many countries, eroding the effectiveness of first-line and even second-line antibiotics.
Another factor is the slow pace of new drug development. As reporting in a recent analysis notes, only a small number of truly novel antibiotics targeting the most dangerous resistant bacteria are in late-stage clinical trials, and commercial incentives for companies remain weak. Without a stronger pipeline, the GRAM baseline scenario assumes that existing drugs will carry most of the load, even as resistance to them intensifies.
Open questions about the AMR death toll and the 2030 target
Several gaps in the evidence limit how precisely anyone can forecast the trajectory. Country-specific projections and detailed uncertainty intervals from the 2024 GRAM study have not been released as open-access data files, making independent verification of regional breakdowns difficult. The modeling necessarily relies on assumptions about future antibiotic development pipelines, government investment in stewardship, and the pace of resistance evolution, all of which could shift substantially depending on policy choices made in the next few years.
The 10 percent reduction target adopted at the UN meeting also lacks a published impact model. No major public document as of late 2024 provides a detailed projection of how meeting that target would change the cumulative 39 million figure. The headline number-495,000 fewer associated deaths per year by 2030 compared with 2019-assumes that reductions achieved by the end of this decade are sustained or improved upon thereafter. In practice, progress could stall, reverse, or accelerate, depending on how seriously governments and health systems pursue implementation.
There are also questions about how the target will be measured. The GRAM framework underpins most global AMR burden estimates, but not every country has the surveillance capacity to generate high-quality local data on resistant infections. In settings where laboratory infrastructure is sparse, estimates rely heavily on statistical modeling and extrapolation from neighboring countries. That approach is necessary to fill gaps, yet it means that apparent changes in AMR-associated deaths over time may partly reflect better data rather than real shifts in disease burden.
Another unresolved issue is whether focusing on associated deaths is the right metric for political accountability. Because associated deaths are more numerous, a 10 percent reduction looks ambitious on paper, but it may be easier to achieve through broad improvements in infection prevention that benefit all patients, not just those with resistant infections. A parallel target framed around attributable deaths-where resistance is clearly the decisive factor-might provide a sharper test of whether policies are truly bending the resistance curve.
For now, the 39 million projection functions as both a warning and a benchmark. It underscores that even if the 2030 target is met, the world will still be living with a level of drug-resistant infection that far exceeds today’s toll. It also highlights where action could have the greatest impact: scaling up vaccination and basic infection control to prevent bacterial diseases in the first place; expanding access to affordable, quality-assured antibiotics so that treatable infections do not become lethal; and investing in new drugs, diagnostics, and surveillance systems that can keep pace with evolving resistance.
Whether the current political commitments are enough will depend on how quickly those practical steps follow. The GRAM analysis shows that the trajectory is not fixed: under more ambitious scenarios with stronger prevention and stewardship, the cumulative death toll falls substantially below 39 million. The question facing governments after the UN meeting is whether they are prepared to treat the 10 percent goal as a minimum starting point-and to build the financing, regulation, and health-system capacity needed to push the curve down much further.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
